HXK2 Antibody refers to monoclonal or polyclonal antibodies designed to bind specifically to hexokinase II, a 100-kDa enzyme encoded by the HK2 gene on human chromosome 2. This enzyme catalyzes the ATP-dependent phosphorylation of glucose to glucose-6-phosphate, the rate-limiting step in glycolysis . HXK2 is overexpressed in cancers and insulin-responsive tissues, making it a key biomarker for metabolic and oncological studies .
HXK2’s roles include:
Metabolic Regulation: Localizes to mitochondria to couple glycolysis with oxidative phosphorylation .
Anti-Apoptotic Activity: Binds VDAC to inhibit cytochrome c release and promote cell survival .
Nuclear Functions: In yeast, HXK2 regulates glucose repression of genes by translocating to the nucleus under high glucose .
Immune Modulation: In breast cancer, HXK2 upregulates PD-L1 expression, suppressing CD8⁺ T-cell infiltration and correlating with poor prognosis .
HXK2 antibodies are used in:
Western Blotting: Detects ~100–105 kDa bands in tissues like skeletal muscle and cancer cell lines .
Immunohistochemistry (IHC): Identifies HXK2 overexpression in breast, glioblastoma, and renal cancers .
Immunofluorescence (IF): Visualizes mitochondrial and nuclear localization in yeast and mammalian cells .
Co-Immunoprecipitation: Validates interactions with VDAC, Mig1, and Bcl-Xl .
Diagnostic Use: HXK2 IHC staining distinguishes malignant tissues (e.g., triple-negative breast cancer) from benign lesions .
Therapeutic Target: Inhibiting HXK2 disrupts glycolysis and enhances chemotherapy sensitivity in glioblastoma .
Immune Checkpoint Link: HXK2-mediated PD-L1 upregulation suggests potential for combined metabolic/immune therapies .
KEGG: sce:YGL253W
STRING: 4932.YGL253W